|
KMID : 0939920020340010023
|
|
대한암학회지
2002 Volume.34 No. 1 p.23 ~ p.27
|
|
|
A Phase Ⅱ Study with Gemcitabine and Carboplatin in Patients with Advanced Non-small Cell Lung Cancer
|
|
Bong Seog Kim/Jae Wan Park
Hwan Yang Park/Yong Bae Park/Jung Won Kang/Sung Hung Kim/Gwi Lae Lee/Bong Seog Kim/Yong Ho Roh
|
|
|
Abstract
|
|
|
Purpose: To evaluate the efficacy and safety of gemcitabine and carboplatin (GC) in the treatment of advanced non-small-cell lung cancer (NSCLC).
Materials and methods: Between November 1999 and April 2001, 34 patients were enrolled in this study. The median age was 66 (range: 52-74) years old and all were male. Sixteen patients demonstrated stage IIIB, 15 stage IV, and 3 recurrence of disease after surgery. Twenty-two patients showed a ECOG performance status of 0 or 1 and 12 had 2. Twenty patients presented with squamous cell carcinoma, 11 adenocarcinoma and 3 unclassified NSCLC. The treatment regimen consisted of intravenous carboplatin AUC of 6 on day 1 and gemcitabine 1,250 mg/m2 on day 1 and 8. The treatment was repeated every 28 days. Toxicities were evaluated according to WHO toxicity criteria.
Results: All thirty-four patients were evaluable. Partia responses were observed in 15 patients. The overall response rate was 44% (95% confidence interval: 27-61%) and the median response duration was 26 (range 8-60 ) weeks. The median survival of all patients was 50 (range 8-70 ) weeks. During a total of 144 cycles, granulocytopenia greater than WHO grade 2 occurred in 2%, thrombocytopenia in 2%, and anemia in 3%, respectively. Non- hematologic toxicities were minor and easily controlled.
Conclusion: A combination chemotherapy of intravenous gemcitabine and carboplatin has a relatively high activity with acceptable toxicities in patients with advanced NSCLC.
|
|
|
KEYWORD
|
|
|
Non-small cell lung cancer, Combination chemotherapy, Gemcitabine, Carboplatin,
|
|
|
FullTexts / Linksout information
|
|
 
|
|
|
Listed journal information
|
|
    
|